OSE IMMUNOTHERAPEUTICS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.56 EUR | -0.71% |
|
+3.35% | +29.91% |
| Apr. 17 | OSE: licensing agreement with AbbVie enters into force | CF |
| Apr. 17 | OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Based on current prices, the company has particularly high valuation levels.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +29.91% | 128M | D | ||
| +1.51% | 42.75B | B | ||
| +49.22% | 41.61B | A | ||
| +8.57% | 41.34B | B- | ||
| -12.36% | 26.59B | C | ||
| +8.92% | 25.49B | B- | ||
| -25.13% | 18.12B | B | ||
| +29.17% | 12.24B | C+ | ||
| -3.12% | 11.76B | C+ | ||
| +6.35% | 11B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- OSE Stock
- Ratings OSE Immunotherapeutics
